INTRODUCTION
============

Cystoid macular edema (CME) is the most common cause of visual impairment due to uveitis.[@b1-JOVR-08-47] Treatments that decrease intraocular inflammation can also reduce CME. In some cases, CME persists even after suppressing the inflammation and further treatments are needed to improve visual acuity (VA). These include non-steroidal anti-inflammatory drugs (topical and systemic), corticosteroids (topical, periocular, intravitreal, and systemic) and systemic carbonic anhydrase inhibitors.[@b1-JOVR-08-47]-[@b6-JOVR-08-47]

Intravitreal triamcinolone (IVT) can improve visual acuity and decrease macular edema in patients with uveitis.[@b1-JOVR-08-47]-[@b3-JOVR-08-47] However, IVT entails complications such as increased intraocular pressure (IOP) in vulnerable patients and induced cataract.[@b1-JOVR-08-47]-[@b6-JOVR-08-47] Additionally, the short-term effect of IVT therapy necessitates repeated injections.[@b4-JOVR-08-47]-[@b6-JOVR-08-47] Anti-vascular endothelial growth factor (VEGF) therapy such as intravitreal bevacizumab (IVB) has recently been shown to improve VA and decrease CME in uveitis.[@b7-JOVR-08-47],[@b8-JOVR-08-47]

Only one study in the literature has reported the effect of intravitreal diclofenac (IVD) on CME of different causes in which we reported that IVD may be effective for treatment of CME due to various etiologies including uveitis.[@b9-JOVR-08-47] To the best of our knowledge, no study has evaluated the effect of IVD on uveitic CME. We therefore designed this study to assess the effect of IVD on refractory uveitic CME.

METHODS
=======

In this prospective, interventional case series, 8 eyes of 8 patients with refractory CME secondary to chronic intermediate uveitis received IVD (500 µg/0.1 ml). CME in these patients was recalcitrant to oral treatment as well as intravitreal and periocular injection of corticosteroids, oral immunosuppressive agents (methotrexate) or intravitreal bevacizumab. These eyes had no periocular or intravitreal injections of corticosteroids or bevacizumab over the past six months. CME was confirmed by angiography and optical coherence tomography (OCT). Visual acuity ranged from 5/200 to 20/50. Patients with history of other retinal diseases causing macular edema (such as diabetes or vascular occlusions), monocular patients, candidates for intraocular surgery, subjects with cataracts and media opacities, and patients with history of vitrectomy were excluded.

All patients were first informed of the possible complications of treatment and provided written informed consent. Following a complete history and eye examination, OCT and fluorescein angiography were performed prior to IVD injection. All other medications required for control of uveitis were continued.

The injections were performed on an outpatient basis after anesthesia with topical tetracaine. After the lid speculum was inserted, a few drops of povidone-iodine 5% were instilled in the eye for disinfection. Then 500 µg (0.1 ml) diclofenac was injected intravitreally using a 30-gauge needle on an insulin syringe in the superotemporal quadrant (3.75 mm and 3.25 mm posterior to the limbus for phakic eyes and pseudophakic eyes, respectively).

Follow-up examinations were performed one day and one week after injection taking particular attention to anterior chamber reaction and IOP. Complete examinations were performed by a masked examiner 12, 24 and 36 weeks after IVD injection. These examinations included measurement of best-corrected visual acuity (BCVA) (measured with a Snellen chart), anterior chamber inflammation, lens opacity, macular status, IOP and use of antiglaucoma medications. Serious injection-related complications such as retinal detachment, intravitreal hemorrhage, endophthalmitis and retinal tear were also recorded. Retinal thickness was measured with a spectral domain OCT (3D OCT-1000, Topcon Corporation, Tokyo, Japan) at baseline and at weeks 12, 24 and 36 post-injection.

Main outcome measures were changes in BCVA and central macular thickness (CMT). Wilcoxon signed test was used to compare pre- and post-treatment values. Correlation between CMT and BCVA was tested with Spearman's coefficient (r).

RESUlTS
=======

Mean age of the patients was 47 years. Three patients had history of cataract surgery with intraocular lens implantation. History of IVT, IVB, and trans-septal steroid injections was present in 2, 3, and 1 cases, respectively. Three cases were on oral prednisolone and 3 others, on oral methotrexate both of which were continued during the study period. [Table 1](#t1-JOVR-08-47){ref-type="table"} shows baseline characteristics of the patients and study outcomes including BCVA and CMT at weeks 12, 24 and 36 after IVD injection.

BCVA improved in 3 patients up to week 12; in 2 patients BCVA continued to improve as compared to baseline towards the end of the follow-up. BCVA deteriorated in 2 patients and remained unchanged in 3 patients over 36 weeks of follow-up. Mean BCVA remained relatively stable at 12, 24 and 36 weeks (0.68, 0.70 and 0.64 logMAR, respectively) as compared to baseline (0.71 logMAR). Mean change in BCVA was -0.08±0.24 logMAR from baseline at 36 weeks post-injection. The above mentioned changes failed to reach statistical significance.

CMT decreased from baseline values in 6 eyes after 12 weeks and in 5 eyes after 36 weeks. Mean CMT decreased up to 24 weeks and slightly increased at week 36; however, it remained lower than baseline. Mean changes in CMT from baseline to 36 weeks was -32±180 microns. However none of these changes was statistically significant. [Figure 1](#f1-JOVR-08-47){ref-type="fig"} shows OCT and angiography images of a patient before and 12 weeks after treatment.

There was no significant correlation between changes in CMT and BCVA at any time point (r=0.25, -0.17 and 0.21 at weeks 12, 24 and 36, respectively). As shown in [Figure 2](#f2-JOVR-08-47){ref-type="fig"}, changes in BCVA did not parallel CMT changes.

Mean IOP showed no significant change from baseline (13.4 mmHg) to week 12 (11.8 mmHg) and week 36 (13.8 mmHg). There were no cases of endophthalmitis, vitreous hemorrhage, retinal detachment or other complications.

DISCUSSION
==========

In our series of 8 eyes undergoing IVD injection, BCVA improved in four cases 36 weeks after injection, however mean BCVA showed no significant change up to 36 weeks. CMT improved in 5 patients up to 36 weeks; mean CMT decreased at all follow-up visits as compared to baseline, but these changes also failed to reach statistical significance.

The pathophysiology of CME may help understand the rationale for employing IVD in this study. The inflammatory response to tissue damage results in release of arachidonic acid (AA) from cell membrane phospholipids. AA is converted to prostaglandins (PG) and thromboxane by cyclooxygenase enzymes (COX1 and COX2), and to leukotrienes by 5-lipooxigenase. PGE2 induces the production of VEGF and basic fibroblast growth factor (b-FGF) in cultured Muller cells.[@b10-JOVR-08-47] Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause vascular regression in chronic granulomatous inflammation by suppressing the COX enzymes, which in turn decrease PGE1 and PGE2.[@b11-JOVR-08-47] Diclofenac sodium is an NSAID which blocks both the cyclooxygenase and lipoxygenase pathways similar to corticosteroids.[@b12-JOVR-08-47]

In the present study, BCVA improved in 4 cases 36 weeks after the injection which is comparable to our previous report on IVD for CME of various etiologies.[@b9-JOVR-08-47] Mean BCVA improvement in the present study was 0.07 LogMAR at 36 weeks. This beneficial effect of IVD on refractory uveitic CME does not seem to be as significant as other intravitreal agents including triamcinolone (visual improvement of -0.32±0.32 LogMAR) or bevacizumab (visual improvement of -0.3±0.45 LogMAR).[@b9-JOVR-08-47] Topical NSAIDs have also been shown to be effective in such cases.[@b13-JOVR-08-47],[@b14-JOVR-08-47] For instance, nepafenac 0.1% resulted in BCVA improvement of 0.36±0.20 LogMAR in six eyes with refractory uveitis.[@b15-JOVR-08-47]

CMT was decreased in most of our cases at all follow-up visits; however, this change was small in some eyes and at some follow-up visits which could be attributed to inter-operator variability or to the sensitivity of the OCT machine. In addition, none of the eyes demonstrated a dry macula at any visit explaining the failure of notable visual improvement. As we demonstrated in our previous study, despite CMT reduction, BCVA improvement is not always expected.[@b9-JOVR-08-47]

Diclofenac is a drug with a small molecule (318.13 Daltons) and has a short half-life in the vitreous (2.87 hours).[@b16-JOVR-08-47] Rapid elimination of diclofenac sodium from the vitreous necessitates several intravitreal injections which may be associated with complications such as retinal detachment and endophthalmitis.[@b17-JOVR-08-47],[@b18-JOVR-08-47]

Methods of increasing the half-life of diclofenac in the vitreous should focus on its pharmacokinetic model and lipophilicity, as well as the delivery system.[@b16-JOVR-08-47] An animal study revealed that a less soluble form of the drug, such as diclofenac acid rather than diclofenac sodium salt, will remain in the vitreous cavity for up to 24 days, potentially resulting in therapeutic levels in posterior segment tissues for a few months.[@b19-JOVR-08-47] An effective slow-release delivery system for intravitreal diclofenac is a practical solution to achieve sustained therapeutic levels with the goal of providing prolonged clinical benefit. Moreover, this system helps control the delivered dose and the rate of dosing.[@b20-JOVR-08-47] Studies have shown that liposomal encapsulation of some intravitreal drugs increases activity, prolongs efficacy and reduces toxicity.[@b20-JOVR-08-47],[@b21-JOVR-08-47] Many other drug delivery systems such as biodegradable and non-biodegradable implants, microspheres, nanoparticles, gels and transporter-targeted prodrugs have been proposed to maximize the effects of ophthalmic drugs in the posterior segment. The safety and efficacy of these techniques need to be verified.[@b22-JOVR-08-47] Currently, there is no available study on implementation of these drug delivery strategies for intravitreal diclofenac.

Our intervention was not associated with major complications and systemic side effects. Kim et al[@b23-JOVR-08-47] showed that diclofenac at a dose of 500 µg is not toxic for the rabbit eye based on electroretinographic and histopathologic studies. We also found no toxic effect of 500µg (0.1ml) intravitreal diclofenac in human eyes.[@b9-JOVR-08-47]

The present study has some shortcomings such as small number of patients and lack of a control group. One should also consider the effects of other systemic medications (steroids and methotrexate) which were taken by our patients and the self-subsiding nature of CME over time. Considering the short half life of diclofenac in the vitreous, not performing an earlier CMT measurement (before week 12) is another limitation of our study. Our outcomes suggest a possible beneficial effect from IVD in uveitic CME. However, the outcomes of our study warrant further evaluation with a larger sample size and a randomized clinical trial.
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![A and B. Optical coherence tomography images of a patient before and 2 weeks after intravitreal diclofenac injection. C and D. Fluorescein angiography before and 12 weeks after the injection.](JOVR-08-47f1){#f1-JOVR-08-47}

![Correlation between percent of changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) during follow-up.](JOVR-08-47f2){#f2-JOVR-08-47}

###### 

Demographic and ocular characteristics of patients before treatment and 12, 24 and 36 weeks after intravitreal diclofenac injection

                                                                BCVA (LogMAR)   CMT (microns)                                                                                                                                        
  ------------------------------------------------------------- --------------- --------------- ------- --------------------------------------- -------- -------- -------- -------- -------- --------- --------- --------- --------- ---------
  1                                                             M               OD              56      Intermediate non-granulomatousuveitis   0.60     0.18     0.18     0.18     -0.42    484       270       254       245       -239
  2                                                             F               OS              58      \"                                      0.54     0.54     0.54     0.70     +0.16    437       423       412       407       -30
  3                                                             F               OD              57      \"                                      0.90     1.10     1.2      1.0      +0.1     345       294       187       223       -122
  4                                                             F               OD              41      \"                                      0.78     0.78     1.0      0.60     -0.18    584       756       780       646       +62
  5                                                             F               OS              36      \"                                      0.40     0.50     0.40     0.30     -0.1     518       522       373       288       -230
  6                                                             F               OS              35      \"                                      0.40     0.30     0.40     0.40     0        476       465       437       416       -60
  7                                                             F               OD              47      \" '                                    1.30     0.78     0.78     0.90     -0.4     390       294       452       705       +315
  8                                                             F               OS              43      Intermediate granulomatous uveitis      0.78     1.30     1.10     1.00     +0.22    672       490       437       721       +49
  Mean                                                          \-              \-              47      \-                                      0.71     0.69     0.70     0.64     -0.08    488       439       416       456       -32
  (SD)                                                                                                                                          (0.30)   (0.38)   (0.37)   (0.32)   (0.24)   \(105\)   \(161\)   \(175\)   \(207\)   \(180\)
  P-value forchange from baseline (Wilcoxon Signed rank test)                   0.916           0.686   0.446                                                     0.123    0.208    0.575                                            

BCVA, best-corrected visual acuity; CMT, central macular thickness; M, male; F, female; OD, right eye; OS, left eye; SD, standard deviation
